Manufacturers in life sciences have not only been dealing with a world health crisis while continuing to get products approved and on the market, but they must also contend with dual regulations within the UK and European Union (EU) as a result of Brexit.
Now that the UK has regulatory bodies that are independent from the EU, manufacturers are left to untangle the different requirements they must meet to introduce products to the European market.
This white paper produced by MasterControl outlines the distinct regulatory processes in the EU and the UK and how manufacturers can prepare to meet the present regulatory challenges as well as the ones still ahead.
Download this white paper now to find out:
- The differences between UK and EU regulatory bodies and processes post-Brexit
- The impact of dual quality regulations for medical device and pharma manufacturers
- How a digital QMS reduces the cost and effort of compliance
- What action to take now to get and keep your products on the market